Outlook Therapeutics

Outlook Therapeutics has named Kevin Lundquist chief financial officer effective September 1, 2026. Lundquist brings more than 20 years of experience in corporate finance and capital markets across the pharmaceutical, biotech and medical device sectors; he most recently served as CFO of CapsoVision, where he led the 2025 initial public offering. The appointment follows FDA approval of LYTENAVA; Lawrence Kenyon will resign effective September 1, 2026 and will continue to support the company through September 30. The compensation committee approved an option grant to Lundquist for 500,000 common shares with a four-year vesting schedule. » More on de.investing.com

Outlook Therapeutics reported an adjusted net loss of $10.9 million ($0.09 per share) for Q3 2026 versus $15.8 million ($0.44 per share) a year earlier, while the FDA approved LYTENAVA in the US roughly three weeks before the report. The company had $11.2 million in cash at quarter-end and raised about $51.1 million net via a capital raise after the quarter. Management plans to build a US sales and reimbursement team (around 50 new hires) and expects rising SG&A costs; it forecasts $50–75 million in net sales in the first 12 months after launch (Europe 10–15%). The stock fell premarket as investors weighed the costly launch and uncertainties about reimbursement and market uptake. » More on de.investing.com

Outlook Therapeutics will release results for the past quarter on August 14, 2026. Three analysts expect on average earnings per share of -0.080 USD versus -0.550 USD a year earlier and revenue of around 1.0 million USD (previous year 1.5 million, -35.76%). For the current fiscal year estimates are for an average loss per share of -0.473 USD (previous year -1.790 USD) and annual revenue of about 2.9 million USD (previous year 1.4 million). » More on finanzen.net